U.S. FDA Approves Update To The Label For Winrevair To Include Data From The Phase 3 Hyperion Trial Evaluating Adults Recently Diagnosed With Pulmonary Arterial Hypertension
MRK•FDA updates Winrevair label
- U.S. FDA approves update to the label for Winrevair™ (sotatercept-csrk) to include data from the Phase 3 Hyperion trial evaluating adults recently diagnosed with pulmonary arterial hypertension (PAH, WHO* Group 1 pulmonary hypertension).
